PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
CMS vs. CRSP
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between CMS and CRSP is 0.03, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.0

Performance

CMS vs. CRSP - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in CMS Energy Corporation (CMS) and CRISPR Therapeutics AG (CRSP). The values are adjusted to include any dividend payments, if applicable.

-30.00%-20.00%-10.00%0.00%10.00%20.00%AugustSeptemberOctoberNovemberDecember2025
12.71%
-25.71%
CMS
CRSP

Key characteristics

Sharpe Ratio

CMS:

1.42

CRSP:

-0.67

Sortino Ratio

CMS:

2.01

CRSP:

-0.83

Omega Ratio

CMS:

1.25

CRSP:

0.91

Calmar Ratio

CMS:

1.14

CRSP:

-0.41

Martin Ratio

CMS:

6.25

CRSP:

-0.86

Ulcer Index

CMS:

3.68%

CRSP:

38.85%

Daily Std Dev

CMS:

16.23%

CRSP:

49.94%

Max Drawdown

CMS:

-91.20%

CRSP:

-81.74%

Current Drawdown

CMS:

-4.86%

CRSP:

-80.70%

Fundamentals

Market Cap

CMS:

$20.34B

CRSP:

$3.46B

EPS

CMS:

$3.51

CRSP:

-$2.80

PEG Ratio

CMS:

2.42

CRSP:

-0.21

Total Revenue (TTM)

CMS:

$5.53B

CRSP:

$1.62M

Gross Profit (TTM)

CMS:

$1.69B

CRSP:

-$118.31M

EBITDA (TTM)

CMS:

$2.23B

CRSP:

-$387.56M

Returns By Period

In the year-to-date period, CMS achieves a 2.15% return, which is significantly lower than CRSP's 2.97% return.


CMS

YTD

2.15%

1M

3.53%

6M

12.71%

1Y

24.65%

5Y*

3.80%

10Y*

9.48%

CRSP

YTD

2.97%

1M

0.36%

6M

-25.71%

1Y

-34.62%

5Y*

-7.04%

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

CMS vs. CRSP — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CMS
The Risk-Adjusted Performance Rank of CMS is 8282
Overall Rank
The Sharpe Ratio Rank of CMS is 8686
Sharpe Ratio Rank
The Sortino Ratio Rank of CMS is 8080
Sortino Ratio Rank
The Omega Ratio Rank of CMS is 7777
Omega Ratio Rank
The Calmar Ratio Rank of CMS is 8181
Calmar Ratio Rank
The Martin Ratio Rank of CMS is 8585
Martin Ratio Rank

CRSP
The Risk-Adjusted Performance Rank of CRSP is 1818
Overall Rank
The Sharpe Ratio Rank of CRSP is 1313
Sharpe Ratio Rank
The Sortino Ratio Rank of CRSP is 1313
Sortino Ratio Rank
The Omega Ratio Rank of CRSP is 1616
Omega Ratio Rank
The Calmar Ratio Rank of CRSP is 2121
Calmar Ratio Rank
The Martin Ratio Rank of CRSP is 2727
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

CMS vs. CRSP - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for CMS Energy Corporation (CMS) and CRISPR Therapeutics AG (CRSP). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for CMS, currently valued at 1.42, compared to the broader market-2.000.002.004.001.42-0.67
The chart of Sortino ratio for CMS, currently valued at 2.01, compared to the broader market-4.00-2.000.002.004.002.01-0.83
The chart of Omega ratio for CMS, currently valued at 1.25, compared to the broader market0.501.001.502.001.250.91
The chart of Calmar ratio for CMS, currently valued at 1.14, compared to the broader market0.002.004.006.001.14-0.41
The chart of Martin ratio for CMS, currently valued at 6.25, compared to the broader market-10.000.0010.0020.006.25-0.86
CMS
CRSP

The current CMS Sharpe Ratio is 1.42, which is higher than the CRSP Sharpe Ratio of -0.67. The chart below compares the historical Sharpe Ratios of CMS and CRSP, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00AugustSeptemberOctoberNovemberDecember2025
1.42
-0.67
CMS
CRSP

Dividends

CMS vs. CRSP - Dividend Comparison

CMS's dividend yield for the trailing twelve months is around 3.03%, while CRSP has not paid dividends to shareholders.


TTM20242023202220212020201920182017201620152014
CMS
CMS Energy Corporation
3.03%3.09%3.36%2.91%2.67%2.67%2.43%2.88%2.81%2.98%3.22%3.11%
CRSP
CRISPR Therapeutics AG
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Drawdowns

CMS vs. CRSP - Drawdown Comparison

The maximum CMS drawdown since its inception was -91.20%, which is greater than CRSP's maximum drawdown of -81.74%. Use the drawdown chart below to compare losses from any high point for CMS and CRSP. For additional features, visit the drawdowns tool.


-80.00%-60.00%-40.00%-20.00%0.00%AugustSeptemberOctoberNovemberDecember2025
-4.86%
-80.70%
CMS
CRSP

Volatility

CMS vs. CRSP - Volatility Comparison

The current volatility for CMS Energy Corporation (CMS) is 4.68%, while CRISPR Therapeutics AG (CRSP) has a volatility of 13.43%. This indicates that CMS experiences smaller price fluctuations and is considered to be less risky than CRSP based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


5.00%10.00%15.00%20.00%AugustSeptemberOctoberNovemberDecember2025
4.68%
13.43%
CMS
CRSP

Financials

CMS vs. CRSP - Financials Comparison

This section allows you to compare key financial metrics between CMS Energy Corporation and CRISPR Therapeutics AG. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab